Therapeutic Potential of Apatinib Against Colorectal Cancer by Inhibiting VEGFR2-Mediated Angiogenesis and β-Catenin Signaling.
Xiaomin CaiBin WeiLele LiXiaofeng ChenJing YangXiaofei LiXiaozheng JiangMu LvMingyang LiYumeng LinQiang XuWenjie GuoYanhong GuPublished in: OncoTargets and therapy (2020)
Overall, the results of the present study here indicated that by inhibiting the VEGFR2-β-catenin-mediated malignant phenotype, apatinib significantly suppresses the growth of CRC, suggesting that the use of apatinib is a promising therapeutic strategy for CRC.